Winchester Group’s Biogen BIIB Stock Holding History

Winchester Group’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	$782K	Hold	3,250	–	–	0.17%	122
2013 Q2	$699K	Buy	+3,250	New	+$694K	0.15%	129

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Winchester Group's BIIB Position: Q3 2013 in Review

Winchester Group held its Biogen (BIIB) position steady in Q3 2013 at 3,250 shares worth $782K. The position accounts for 0.17% of the portfolio, ranked #122.

Winchester Group first reported a position in BIIB in Q2 2013 and has held it in 2 quarters since. 656 funds tracked by Wall St. Rank hold BIIB as of Q3 2013.

Winchester Group held 3,250 shares of Biogen worth $782K as of Q3 2013.
Winchester Group left its Biogen share count unchanged in Q3 2013.
Biogen made up 0.17% of Winchester Group's portfolio in Q3 2013, its #122 holding.
Winchester Group first reported a position in Biogen in Q2 2013 and has held it in 2 quarters since.
656 funds tracked by Wall St. Rank held Biogen as of Q3 2013.

Based on Winchester Group's 13F filing for Q3 2013, filed 16 Oct 2013.